PubMed · 15977694
Anthrax vaccines.
Abstract
Anthrax, an uncommon disease in humans, is caused by a large bacterium, Bacillus anthracis. The risk of inhalation infection is the main indication for anthrax vaccination. Pre-exposure vaccination is provided by an acellular vaccine (anthrax vaccine adsorbed or AVA), which contains anthrax toxin elements and results in protective immunity after 3 to 6 doses. Anthrax vaccine precipitated (AVP) is administered at primovaccination in 3 doses with a booster dose after 6 months. To evoke and maintain protective immunity, it is necessary to administer a booster dose once at 12 months. In Russia, live spore vaccine (STI) has been used in a two-dose schedule. Current anthrax vaccines show considerable local and general reactogenicity (erythema, induration, soreness, fever). Serious adverse reactions occur in about 1% of vaccinations. New second-generation vaccines in current research programs include recombinant live vaccines and recombinant sub-unit vaccines.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Miroslav Splino, Jiri Patocka, Roman Prymula, Roman Chlibek. Anthrax vaccines.. https://doi.org/10.5144/0256-4947.2005.143. https://searchpubmed.org/record/pubmed%3A15977694/anthrax-vaccines
Citations retain the original authors and DOI and include this site’s record URL. If this discovery service contributed to your research, you can also cite Search PubMed by Indiciae: BibTeX · RIS.